ESMO/ECCO to host combined meetings

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Over 80% of a small cohort of patients with mantle cell lymphoma achieved a complete response to ibrutinib plus venetoclax.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Nadunolimab Exhibits Comparable Efficacy Vs Chemotherapy Alone in TNBC

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Roman Fabbricatore

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD

December 1st 2025

FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.

Tim Cortese

ASH 2025: Key Anticipated Updates in the Leukemia Landscape

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.

Updated results at ASH 2025 may support new alternatives to continuous therapy and standard intensive chemotherapy across different leukemia types.

Ibrutinib/Venetoclax Yields Long-Term Efficacy in Japanese R/R MCL Trial

Updated results at ASH 2025 may support new alternatives to continuous therapy and standard intensive chemotherapy across different leukemia types.

Related Content

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Over 80% of a small cohort of patients with mantle cell lymphoma achieved a complete response to ibrutinib plus venetoclax.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Nadunolimab Exhibits Comparable Efficacy Vs Chemotherapy Alone in TNBC

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Roman Fabbricatore

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD

December 1st 2025

FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Tim Cortese

ASH 2025: Key Anticipated Updates in the Leukemia Landscape

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.